Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.46
XOMA's Cash to Debt is ranked lower than
87% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. XOMA: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
XOMA' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1 Max: No Debt
Current: 0.46
Equity to Asset -1.26
XOMA's Equity to Asset is ranked lower than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XOMA: -1.26 )
Ranked among companies with meaningful Equity to Asset only.
XOMA' s Equity to Asset Range Over the Past 10 Years
Min: -1.26  Med: -0.02 Max: 0.54
Current: -1.26
-1.26
0.54
F-Score: 2
Z-Score: -65.10
M-Score: -0.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -28.86
XOMA's Operating margin (%) is ranked higher than
61% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. XOMA: -28.86 )
Ranked among companies with meaningful Operating margin (%) only.
XOMA' s Operating margin (%) Range Over the Past 10 Years
Min: -433.75  Med: -104.78 Max: 13.17
Current: -28.86
-433.75
13.17
Net-margin (%) -20.10
XOMA's Net-margin (%) is ranked higher than
62% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. XOMA: -20.10 )
Ranked among companies with meaningful Net-margin (%) only.
XOMA' s Net-margin (%) Range Over the Past 10 Years
Min: -349.94  Med: -121.15 Max: 0.56
Current: -20.1
-349.94
0.56
ROA (%) -19.83
XOMA's ROA (%) is ranked higher than
59% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. XOMA: -19.83 )
Ranked among companies with meaningful ROA (%) only.
XOMA' s ROA (%) Range Over the Past 10 Years
Min: -108.21  Med: -51.27 Max: 0.92
Current: -19.83
-108.21
0.92
ROC (Joel Greenblatt) (%) -306.69
XOMA's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. XOMA: -306.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XOMA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1636.29  Med: -304.24 Max: 46.51
Current: -306.69
-1636.29
46.51
Revenue Growth (3Y)(%) -3.40
XOMA's Revenue Growth (3Y)(%) is ranked lower than
59% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. XOMA: -3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XOMA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.8  Med: -21.3 Max: 148.1
Current: -3.4
-60.8
148.1
EBITDA Growth (3Y)(%) -49.30
XOMA's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. XOMA: -49.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XOMA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.3  Med: -21.5 Max: 31
Current: -49.3
-49.3
31
EPS Growth (3Y)(%) -46.30
XOMA's EPS Growth (3Y)(%) is ranked lower than
87% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. XOMA: -46.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XOMA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.4  Med: -13.6 Max: 35
Current: -46.3
-52.4
35
GuruFocus has detected 3 Warning Signs with XOMA Corp $XOMA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XOMA's 10-Y Financials

Financials (Next Earnings Date: 2017-03-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

XOMA Guru Trades in

XOMA Guru Trades in

Q3 2016

XOMA Guru Trades in Q3 2016

Jim Simons 193,095 sh (New)
Paul Tudor Jones 30,725 sh (New)
» More
Q4 2016

XOMA Guru Trades in Q4 2016

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:EARS, NAS:APOP, NAS:PRTO, OTCPK:RGRX, NAS:RPRX, AMEX:OGEN, OTCPK:FENCF, AMEX:BPMX, AMEX:MSTX, NAS:VKTX, OTCPK:EMIS, OTCPK:ONCYF, NAS:RTTR, NAS:BLPH, NAS:NVLS, NAS:ADHD, NAS:MRNS, OTCPK:BIOAF, AMEX:IBIO, NAS:CLRB » details
Traded in other countries:X0M1.Germany,
XOMA Corp discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites.

XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.

Ratios

vs
industry
vs
history
P/S 0.58
XOMA's P/S is ranked higher than
98% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. XOMA: 0.58 )
Ranked among companies with meaningful P/S only.
XOMA' s P/S Range Over the Past 10 Years
Min: 0.45  Med: 3.74 Max: 37.15
Current: 0.58
0.45
37.15
Current Ratio 0.98
XOMA's Current Ratio is ranked lower than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. XOMA: 0.98 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.96 Max: 6.43
Current: 0.98
0.63
6.43
Quick Ratio 0.98
XOMA's Quick Ratio is ranked lower than
85% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. XOMA: 0.98 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.94 Max: 6.43
Current: 0.98
0.63
6.43
Days Sales Outstanding 5.18
XOMA's Days Sales Outstanding is ranked higher than
91% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. XOMA: 5.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.18  Med: 66.02 Max: 226.37
Current: 5.18
5.18
226.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.00
XOMA's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. XOMA: -13.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XOMA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -82.3  Med: -14.9 Max: -6.5
Current: -13
-82.3
-6.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.16
XOMA's Price/Median PS Value is ranked higher than
95% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. XOMA: 0.16 )
Ranked among companies with meaningful Price/Median PS Value only.
XOMA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 2.89 Max: 192.53
Current: 0.16
0.15
192.53
Earnings Yield (Greenblatt) (%) -11.80
XOMA's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. XOMA: -11.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XOMA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11.8  Med: 11 Max: 19.6
Current: -11.8
-11.8
19.6

More Statistics

Revenue (TTM) (Mil) $53.22
EPS (TTM) $ -1.65
Beta2.78
Short Percentage of Float9.09%
52-Week Range $3.96 - 23.00
Shares Outstanding (Mil)6.05

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 6 10 14 41
EPS ($) -6.46 -6.27 -5.45 -4.51
EPS w/o NRI ($) -6.46 -6.27 -5.45 -4.51
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to... Feb 16 2017
XOMA Appoints Matthew Perry to its Board of Directors Feb 16 2017
Biotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA Feb 15 2017
Xoma Launches $25 Million Registered Offering Feb 13 2017
XOMA CORP Files SEC form 8-K, Other Events Feb 13 2017
XOMA Announces Pricing of $25 Million Registered Offering of Common Stock and Convertible Preferred... Feb 13 2017
XOMA Says Its Drug Candidate 358 Is Progressing Feb 01 2017
XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia... Jan 31 2017
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 17 2017
13 Emerging Biotechs With Catalysts In 2017 Jan 03 2017
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition... Dec 22 2016
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements... Dec 21 2016
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements... Dec 21 2016
ETFs with exposure to XOMA Corp. : December 16, 2016 Dec 16 2016
How XOMA Corp (XOMA) Stacks Up Against Its Peers Dec 12 2016
ETFs with exposure to XOMA Corp. : December 5, 2016 Dec 05 2016
XOMA CORP Financials Nov 17 2016
ETFs with exposure to XOMA Corp. : November 16, 2016 Nov 16 2016
XOMA Challenged With A 'Major Financing Overhang' Nov 15 2016
XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)